Skip to content

Translational-Omics in Aortic Stenosis (TOmAS) Biobank

Cardiovascular Diseases | Aortic Valve Stenosis

The objective of the TOmAS Biobank is the conservation of biological material (plasma, saliva, and tissue explanted during surgery), genetic material (DNA, RNA, etc.), and clinical data ("material/data") collected from patients with cardiovascular diseases (CVD) as well as from control participants, in order to allow future studies evaluating novel proteomic, transcriptomic and epigenomic markers (as well as other emerging -omic technologies) for CVD (i.e. aortic stenosis, cardiomyopathy, myorcardial infarction, etc). The study of physiological and genetic factors will allow for the discovery of new genomic and other -omic (including proteomic, transcriptomic and epigenomic) biomarkers associated with CVD which will lead to an improved understanding of the underlying biology of CVD and may provide future insights into the prevention and treatment of this type of disease.

null

Participation Requirements

  • Sex:

    ALL

  • Eligible Ages:

    19 and up

Participation Criteria

Inclusion Criteria:

* CVD diagnosis including, but not limited to: Aortic Stenosis, Coronary Heart Disease, Heart Failure, Atrial Fibrilation, Dilated Cardiomyopathy, Myocardial Infarction, and Spontaneous Coronary Artery Dissection.
* Undergoing cardiac surgery for non-aortic valve pathology

Exclusion Criteria:

* Individuals with Congenital heart disease will be excluded

Study Location

Montreal General Hospital
Montreal General Hospital
Montréal, Quebec
Canada

Contact Study Team

Primary Contact

George Thanassoulis, MD

[email protected]
5142340818
Royal Victoria Hospital
Royal Victoria Hospital
Montréal, Quebec
Canada

Contact Study Team

Primary Contact

George Thanassoulis, MD

[email protected]
5149341934
Study Sponsored By
McGill University Health Centre/Research Institute of the McGill University Health Centre
Participants Required
More Information
Study ID: NCT05930899